ERBB3 and cancer: NRG1/HER3‐activated signalling pathways (e.g. PI3K‐AKT) promote cell proliferation, migration and survival [18, 19, 20, 21, 22, 29], while blocking of NRG1‐mediated HER3 activation inhibits migration and growth of cancer cells in preclinical models [30, 31].